No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
100 |
4. Check minimum number of eventsNone |
100 |
5. Include endpointsNone |
100 |
6. Filter based on genotype QC (FinnGen only) |
97 |
Control definitions (FinnGen only)
- Control exclude
- N14_GLOMERULAR
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- N00-N08
- Name in latin
- Nephropathia hereditaria non alibi classificata
Similar endpoints
↥List of similar endpoints to
Hereditary nephropathy, not elsewhere classified
based on the number of shared cases.
Similar with more cases:
- Glomerulonephritis
- Glomerular diseases
- All chronic kidney diseases
- All kidney diseases
- Genitourinary diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 696 | 397 | 292 |
| Only index persons | 604 | 359 | 245 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 56.77 | 56.15 | 57.22 |
| Only index persons | 54.59 | 53.86 | 55.65 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 97 | 51 | 46 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 57.73 | 54.87 | 60.90 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 100
- Matched controls
- 1000
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N07.4
ICD-10 Finland
Hereditary nephropathy, not elsewhere classified, diffuse endocapillary proliferative glomerulonephritis
+∞
46.5
41
*
N07.3
ICD-10 Finland
Hereditary nephropathy, not elsewhere classified, diffuse mesangial proliferative glomerulonephritis
+∞
35.6
32
*
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
51.9
23.1
27
7
L40.5
ICD-10 Finland
Arthropathic psoriasis
46.8
21.0
25
7
M07.3
ICD-10 Finland
Other psoriatic arthropathies
92.7
20.6
22
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
6.1
14.9
33
75
R07.4
ICD-10 Finland
Chest pain, unspecified
4.7
13.3
52
188
L01BA01
ATC
methotrexate; systemic
14.4
12.0
20
17
E000001, ,
ATC
4.3
10.4
36
116
L04AX03
ATC
methotrexate; systemic
5.0
9.6
24
59
L04AA01
ATC
[U] ciclosporin
+∞
9.5
9
*
N07.9
ICD-10 Finland
Hereditary nephropathy, not elsewhere classified, unspecified
+∞
9.5
9
*
D05AX02
ATC
calcipotriol; topical
13.3
9.5
16
14
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.3
9.4
30
90
E0000UV, ,
ATC
3.6
9.2
57
268
A06AD11
ATC
lactulose; oral
4.1
9.0
31
98
SPAT1148
SPAT
Treatment of chronic ulcer or burn
4.3
8.7
27
79
M07.0*L40.5
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
98.0
8.6
9
*
J01FF01
ATC
clindamycin; systemic
3.5
8.5
44
183
L40.0
ICD-10 Finland
Psoriasis vulgaris
9.5
8.5
17
21
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
3.3
7.9
51
241
A11CC03
ATC
alfacalcidol; systemic
20.3
7.8
11
6
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
27.5
7.7
10
*
H02AB07
ATC
prednisone; oral
4.0
7.6
26
81
6960A
ICD-9 Finland
Psoriasis and similar disorders, Psoriatic arthropathy
+∞
7.4
7
*
N07.0
ICD-10 Finland
Hereditary nephropathy, not elsewhere classified, minor glomerular abnormality
+∞
7.4
7
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
8.1
7.4
16
23
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
7.4
7.3
17
27
R52.9
ICD-10 Finland
Pain, unspecified
4.6
7.1
19
49
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
13.5
6.8
11
9
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
13.5
6.8
11
9
D05AX52
ATC
calcipotriol, combinations; topical
6.8
6.6
16
27
A02BC03
ATC
lansoprazole; oral
3.0
6.5
45
217
L04AB01
ATC
etanercept; parenteral
28.7
6.3
8
*
JN3AD
NOMESCO Finland
Abdominal CT examination
3.8
6.3
22
69
M07.0
ICD-10 Finland
Distal interphalangeal psoriatic arthropathy
+∞
6.3
6
*
M04AA01
ATC
allopurinol; systemic
3.5
6.3
25
86
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
3.3
6.3
29
110
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.9
6.2
42
199
R50.9
ICD-10 Finland
Fever, unspecified
3.3
6.1
28
105
C03CA01
ATC
furosemide; systemic
2.9
6.1
47
237
N02BF02
ATC
pregabalin; oral
6.6
6.1
15
26
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.0
6.1
19
55
XF400
NOMESCO Finland
ECG with 12 standard connections
3.2
6.1
29
112
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
16.3
6.0
9
6
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
72
429
3.42
7.34
22.6
6.2
1.21
1.22
mmol/l
0.40
64
364
31
114
3.49
7.10
30.4
6.1
104.68
103.82
mmol/l
0.29
31
114
59
345
2.73
5.66
6.3
4.1
30.15
40.07
ng/l
0.37
40
253
17
52
3.73
5.01
4.4
3.4
1.45
1.69
mmol/l
—
8
38
63
400
2.55
4.84
23.2
5.5
1.22
1.21
mmol/l
0.12
58
355
18
59
3.50
4.80
2.9
1.5
—
—
—
0
0
33
155
2.69
4.75
6.6
2.7
0.53
0.84
e6/l
0.68
27
90
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
11
18
6.72
4.75
6.6
2.2
0.35
0.36
u/ml
—
6
8
7
5
14.89
4.64
20.4
8.0
12.56
12.80
mg/l
—
7
5
59
371
2.44
4.52
8.4
4.1
34.38
35.04
g/l
0.31
54
348
62
406
2.39
4.24
22.0
13.3
1.19
1.23
inr
0.13
15
117
52
317
2.33
4.18
7.6
3.3
—
—
—
0
0
17
63
3.05
3.71
6.9
4.0
49.43
55.87
ml/min/173m2
—
7
31
60
403
2.22
3.66
7.5
4.1
0.00
0.00
estimate
-0.00
12
89
60
403
2.22
3.66
10.9
5.6
0.00
0.00
estimate
-0.00
12
81
15
52
3.22
3.65
65.1
7.9
23.83
24.51
mmol/l
0.34
15
52
43
254
2.22
3.60
7.7
3.0
0.43
0.49
e6/l
0.10
38
187
29
147
2.37
3.46
7.4
2.9
2.67
2.55
e6/l
0.02
23
83
14
49
3.16
3.35
5.0
3.5
0.01
0.18
e6/l
1.46
14
49
59
405
2.11
3.28
7.5
4.1
0.00
0.00
estimate
-0.00
12
79
11
30
3.99
3.20
1.1
1.3
—
—
—
0
0
52
345
2.06
3.12
3.6
2.3
76.29
76.30
nmol/l
0.00
45
299
24
117
2.38
3.09
4.2
2.1
11.77
14.53
umol/l
0.95
24
108
33
185
2.17
3.07
4.5
1.6
0.96
1.22
mg/l
0.49
26
146
27
140
2.27
3.03
2.3
1.9
—
—
—
0
0
29
157
2.19
2.93
5.9
3.4
471.45
151.05
ng/l
0.67
20
130
46
298
2.01
2.89
4.3
3.3
2.34
2.36
mmol/l
0.63
39
257
11
34
3.51
2.83
1.7
1.6
—
—
—
0
0
5
6
8.68
2.78
3.2
3.7
—
—
—
0
0
14
55
2.80
2.75
44.2
8.8
93.91
94.42
%
0.27
14
55
67
504
2.00
2.66
19.7
4.6
7.06
6.67
mmol/l
0.75
67
468
20
97
2.33
2.59
1.8
1.8
—
—
—
0
0
17
79
2.39
2.41
3.8
2.5
0.20
0.22
g/l
0.32
17
70
46
313
1.87
2.40
7.0
4.3
—
—
—
0
0
13
53
2.67
2.39
1.4
1.4
—
—
—
0
0
37
237
1.89
2.31
6.2
3.3
35.88
6.46
mg/mmol
1.10
30
138
7
18
4.10
2.29
2.3
1.3
—
—
—
0
0
5
9
5.78
2.24
1.2
1.3
—
—
—
0
0
7
20
3.68
2.09
15.0
1.6
207.14
199.00
%
—
7
20
5
10
5.20
2.09
1.0
1.0
—
—
—
0
0
5
10
5.20
2.09
1.2
1.3
—
—
—
0
0
11
44
2.69
2.09
25.5
2.9
0.84
0.73
%
0.21
11
44
11
44
2.69
2.09
6.5
2.8
25.08
24.65
mmol/l
0.23
11
44
19
100
2.11
2.02
1.8
1.9
—
—
—
0
0
11
45
2.62
2.01
25.5
2.8
1.93
1.16
%
0.39
11
45
12
52
2.49
1.96
25.8
2.9
122.17
131.42
g/l
1.05
12
52
11
46
2.56
1.93
7.7
3.1
47.56
45.97
%
0.09
11
46
8
28
3.01
1.91
1.0
1.4
—
—
—
0
0
12
53
2.44
1.89
1.3
1.7
—
—
—
0
0
25
152
1.86
1.79
1.3
1.3
1.32
2.37
u/ml
—
10
59
33
219
1.76
1.78
6.3
4.3
0.00
0.00
estimate
—
10
80
8
30
2.81
1.76
1.3
1.5
0.25
0.21
g/l
—
8
30
7
25
2.93
1.68
13.3
1.4
90.29
92.44
%
—
7
25
5
14
3.70
1.63
1.8
1.3
—
—
—
0
0
5
15
3.45
1.54
1.6
1.5
—
—
—
0
0
5
15
3.45
1.54
1.6
1.5
—
—
—
0
0
5
15
3.45
1.54
1.2
1.5
—
—
—
0
0
6
21
2.97
1.53
1.7
1.5
—
—
—
0
0
6
21
2.97
1.53
1.0
1.6
—
—
—
0
0
6
21
2.97
1.53
1.7
1.5
—
—
—
0
0
45
341
1.58
1.41
2.4
1.9
90.75
92.66
pmol/l
0.11
22
162
77
663
1.70
1.41
16.5
8.1
89.63
82.00
u/l
0.33
72
616
26
172
1.69
1.39
1.8
1.7
795.11
1236.78
nmol/l
2.06
17
136
90
813
2.07
1.37
39.6
15.5
19.30
22.32
mg/l
0.63
83
658
48
373
1.55
1.33
4.3
2.6
—
—
—
0
0
26
176
1.64
1.27
1.7
1.8
512.33
453.78
pmol/l
0.22
21
147
20
126
1.73
1.27
1.5
1.5
—
—
—
0
0
26
177
1.63
1.25
1.5
1.2
0.53
1.79
u/ml
—
8
53
64
536
1.54
1.23
6.2
3.1
87.31
49.27
u/l
1.17
55
503
30
214
1.57
1.19
1.8
1.4
18.17
22.98
nmol/l
1.08
25
176
8
40
2.09
1.15
1.0
1.0
—
—
—
0
0
7
31
2.35
1.13
3.0
1.9
—
—
—
0
0
7
32
2.27
1.10
3.6
2.1
—
—
—
0
0
7
32
2.27
1.10
5.6
2.2
—
—
—
0
0
59
493
1.48
1.09
2.8
3.0
—
—
—
0
0
7
34
2.14
1.05
1.1
1.6
—
—
—
0
0
5
22
2.34
1.04
1.4
1.6
—
—
—
0
0
5
22
2.34
1.04
1.6
1.6
—
—
—
0
0
27
194
1.54
1.03
5.1
2.3
—
—
—
0
0
82
740
1.60
0.99
6.1
4.9
1.91
1.96
mu/l
0.12
74
657
15
97
1.64
0.87
1.9
1.3
—
—
—
0
0
23
168
1.48
0.81
2.0
3.2
2.42
2.46
mmol/l
1.00
18
144
5
25
2.05
0.74
1.8
1.3
—
—
—
0
0
7
40
1.81
0.73
1.1
1.2
—
—
—
0
0
8
51
1.62
0.62
10.0
2.9
4.61
4.39
pmol/l
—
8
41
81
753
1.40
0.60
7.3
5.8
43.07
39.83
mmol/mol
1.65
75
701
5
32
1.59
0.43
1.2
1.1
—
—
—
0
0
5
32
1.59
0.43
1.2
1.1
—
—
—
0
0
81
770
1.27
0.36
28.4
14.5
72.44
79.30
ml/min/173m2
1.37
72
627
79
756
1.21
0.28
5.3
4.1
1.36
1.28
mmol/l
0.41
71
685
0
12
0.00
0.21
0.0
1.1
—
1.72
—
0
5
11
91
1.23
0.18
12.5
8.8
—
—
—
0
0
80
779
1.13
0.14
6.2
4.7
6.09
5.95
mmol/l
0.41
70
703
19
210
0.88
0.13
4.2
4.5
21.66
21.83
%
—
8
100
87
852
1.16
0.13
41.6
18.2
91.56
77.72
umol/l
1.44
87
852
82
804
1.11
0.10
6.2
5.1
2.55
2.71
mmol/l
0.78
74
733
5
60
0.82
0.08
1.8
1.7
—
—
—
0
0
14
151
0.92
0.05
3.1
2.9
0.52
0.66
ug/l
—
9
105
90
890
1.11
0.05
61.1
22.6
39.05
40.04
%
0.79
85
846
80
789
1.07
0.05
5.8
4.6
4.46
4.63
mmol/l
0.68
74
725
80
789
1.07
0.05
5.8
4.5
1.45
1.48
mmol/l
0.18
73
718
0
9
0.00
0.00
0.0
2.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
38.38
—
0
6
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
6
66
0.90
-0.00
1.7
1.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
9.64
—
0
8
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
43.32
—
0
5
0
6
0.00
-0.00
0.0
2.2
—
17.25
—
0
6
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
8
80
1.00
-0.00
4.8
4.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint N14_NEPHROPATHYHER and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| N14_NEPHROPATHYHER | 1.877 [1.41, 2.5] | < 0.001 |
| Birth year | 0.999 [0.99, 1.01] | 0.831 |
During the follow-up period (1.1.1998 — 31.12.2019), 104 out of 364 females with N14_NEPHROPATHYHER died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| N14_NEPHROPATHYHER | 2.079 [1.56, 2.77] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 106 out of 265 males with N14_NEPHROPATHYHER died.
Mortality risk
Mortality risk for people of age
years, who have N14_NEPHROPATHYHER.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.211% | 0.338% |
| 5 | 1.2% | 2.306% |
| 10 | 3.01% | 5.455% |
| 15 | 5.937% | 10.541% |
| 20 | 10.864% | 17.371% |
Relationships between endpoints
↥Index endpoint: N14_NEPHROPATHYHER – Hereditary nephropathy, not elsewhere classified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data